User Fees for Generic Drugs: A Foregone Conclusion?

By Chi, Judy | Drug Topics, March 3, 1997 | Go to article overview

User Fees for Generic Drugs: A Foregone Conclusion?


Chi, Judy, Drug Topics


Now that user fees appear to be working well for brand-name drug companies, the generic drug industry is toying with the concept.

Under the user-fee system, manufacturers agree to pay the Food & Drug Administration a certain fee per application to enable the agency to hire more staffers to expedite the review of their Abbreviated New Drug Applications (ANDAs).

At the recent National Association of Pharmaceutical Manufacturers' annual meeting, held in Naples, Fla., president Robert Milanese reported that the NAPM's board has decided to negotiate user fees with the FDA and Congress.

Dissatisfied with the speed with which ANDAs are currently approved, NAPM members would consider paying user fees in return for performance guarantees from the FDA. Swifter approval of generics would make available more affordable drugs to consumers.

Not that all NAPM board members favor this position. In fact, two NAPM board members abstained from voting on this issue since they were opposed. Said one board member at the meeting who did not wish to be identified, "I am philosophically and irrevocably opposed" to user fees. By statute, the FDA is supposed to review each ANDA within 180 days. Opponents of user fees don't see why they should pay the agency a fee for something that it should be doing anyway. User fees also don't sit well with the smaller generic companies, which may have a more difficult time making the payment, estimated at almost $50,000 per application.

On the other hand, many generic firms say that user fees make sense since the FDA is in a Catch 22 position: It has been receiving an increasing number of ANDA submissions per year but has been given diminishing resources in today's climate of government downsizing. User fees would be a welcome relief for the FDA's Office of Generic Drugs. An attendee at the NAPM meeting admitted as much when he told Drug Topics, "User fees are a good idea. After all, there's no free lunch."

Support for user fees also stems from the fact that they've worked well for innovator drug companies. Passed in 1992, the Prescription Drug User Fee Act (PDUFA) has accelerated the review of brand-name drug applications. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • A full archive of books and articles related to this one
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

User Fees for Generic Drugs: A Foregone Conclusion?
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

    Already a member? Log in now.